Těžké astma

Postery prezentované na AAAAI Annual Meeting, San Francisco, CA, USA, 22.–25. února, 2019

			Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab (staženo 9× )
			High peripheral blood eosinophil levels are associated with low FEV1 reversibility in patients with severe eosinophilic asthma (staženo 8× )
			Evaluation of eosinophilic asthma patients without blood eosinophil (EOS) response to intravenous (IV) reslizumab in a post-hoc analysis of 52-week placebo-controlled Phase 3 studies (staženo 7× )
			A high proportion of exacerbation-prone patients with uncontrolled eosinophilic asthma receiving intravenous (IV) reslizumab experienced zero asthma exacerbations through 52 weeks of treatment (staženo 7× )
			Variability in absolute blood eosinophil (EOS) counts over 52 weeks in patients with inadequately controlled eosinophilic asthma receiving placebo in two duplicate clinical trials (staženo 7× )

Odborné texty

			Novosad J, Krčmová I. Reslizumab. Remedia 2/2019 (staženo 66× )
			Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab (staženo 54× )
			Reslizumab v terapii pacientů s nedostatečně kontrolovaným eozinofilním astmatem (staženo 222× )